Mechanism of the inhibitory effect of ghrelin in sepsis

Asha Jacob
Rongqian Wu
Mian Zhou
Gene F Coppa
Ping Wang

Department of Surgery, North Shore University Hospital and Long Island Jewish Medical Center, and The Feinstein Institute for Medical Research, Manhasset, NY, USA

Correspondence: Ping Wang
Laboratory of Surgical Research, The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
Tel +1 516 562-3411
Fax +1 516 562-1022
Email pwang@nshs.edu

Abstract: Sepsis and septic shock are the leading causes of death in intensive care units. Approximately 40%–70% of the mortality rate is associated with severe sepsis and septic shock. Systemic antibiotic usage, surgical intervention, aggressive fluid resuscitation and careful monitoring are common measures currently used to treat sepsis. Despite advances in the understanding of the pathophysioglogy of sepsis, very little progress has been made towards therapeutic interventions. Recently we have shown that ghrelin, a stomach-derived peptide which is an endogenous ligand for the growth hormone secretagogue receptor (GHSR-1a), is beneficial in attenuating the inflammatory response, organ injury and mortality in an experimental model of polymicrobial sepsis induced by cecal ligation and puncture (CLP). In this review, we describe the mechanism of action of ghrelin in sepsis, highlight the role ghrelin plays in attenuating the hepatic dysfunction induced by sepsis and septic shock and suggest in developing ghrelin as a potential therapy for sepsis.

Keywords: ghrelin, sepsis, inhibition septic shock, GHSR-1a, cecal ligation

Introduction

Sepsis and septic shock continue to be common causes of death in intensive care units. Septic shock and multi-organ dysfunction are the predominant causes of death in patients with sepsis. The incidence of severe sepsis in the United States is estimated to be 750,000 cases per year and continues to increase at a rate of 1.5% annually.1 Approximately 40%–70% of the mortality rate is associated with severe sepsis and septic shock.2 Despite advances in the understanding of the pathophysiology of sepsis, very little improvement has been made in therapeutic interventions. In this review, we provide a brief overview of the pathophysiology of sepsis as it relates to hepatic dysfunction and describe the preclinical studies detailing the mechanism of action of ghrelin, a novel stomach-derived peptide that could be developed as a potential therapy for sepsis.

Hepatic dysfunction in sepsis

Due to its integral role in metabolism and host defense mechanisms, liver is believed to be the major organ responsible for initiating multiple organ failure during sepsis.3 The cardiovascular responses to polymicrobial sepsis induced by cecal ligation and puncture (CLP) in rats is characterized by an early hyperdynamic phase (2–5 hours after CLP) associated with the increased cardiac output and decreased vascular resistance followed by a late phase (20 hours after CLP) which involved the decreased cardiac output and increased vascular resistance.4 Previous studies have indicated that hepatic function is depressed early after the onset of sepsis during the hyperdynamic response phase.5

1. Jacob et al. 2010
2. Unknown author.
3. Unknown author.
4. Unknown author.
5. Unknown author.
This hepatic dysfunction is a consequence of the upregulated pro-inflammatory cytokine production by the Kupffer cells, the resident macrophages of the liver.\textsuperscript{5–7}

Upregulation of cytokines is, in part, caused by the increased release of the sympathetic neurotransmitter, norepinephrine (NE) from the gut during sepsis. This is evidenced by our studies\textsuperscript{8} and others\textsuperscript{9} which show that peripheral sympathetic activity increases during sepsis resulting in the elevation of plasma levels of NE. In addition, enterectomy prior to onset of sepsis markedly reduced circulating levels of NE.\textsuperscript{10} This indicates that the gut is the major source of NE release during sepsis. About 50\% of the NE released in the body is produced by the sympathetic fibers in the gut.\textsuperscript{11,12} Interestingly, NE levels in the portal blood during sepsis are significantly higher than those in the systemic circulation. Intraportal infusion of NE \textit{in vivo} increased TNF-\(\alpha\) release and was inhibited by co-infusion with yohimbine, a non-specific antagonist of the \(\alpha_2\)-adrenoceptor.\textsuperscript{13} Cellular levels of TNF-\(\alpha\) in Kupffer cells were also significantly increased following intraportal NE infusion and were inhibited by co-infusion with yohimbine.

The increase in TNF-\(\alpha\) release was abrogated by co-administration of intraportal infusion of NE and the specific \(\alpha_2\_\alpha\) antagonist, BRL-4408 maleate.\textsuperscript{14} Kupffer cells isolated from rats during early sepsis (2 hours after CLP) exhibited marked increase in \(\alpha_2\_\alpha\)-adrenoceptor mRNA expression.\textsuperscript{15} Recently, we showed that mitogen activated protein kinase (MAPK) phosphatase-1 (MKP-1) is significantly decreased in the liver during sepsis and this decrease is correlated at least in \textit{in vitro}, by the activation of NE on Kupffer cells.\textsuperscript{16} In addition, intraportal infusion with NE \textit{in vivo} in normal rats significantly decreased MKP-1 mRNA expression.\textsuperscript{17} These studies collectively suggest that NE released from the gut during the early stage of sepsis travels through the portal vein, binds to \(\alpha_2\_\alpha\)-adrenoceptor on Kupffer cells, possibly down regulates MKP-1 leading to uncontrolled activation of MAPKs, and facilitates the increased production of TNF-\(\alpha\) thereby causes hepatic dysfunction (Figure 1).

**Role of ghrelin in sepsis**

Ghrelin was first identified from the rat stomach about a decade ago\textsuperscript{16} and has demonstrated to be a strong stimulator of growth hormone secretion in the rat and human.\textsuperscript{17–19} Ghrelin mediates its effects by binding to the growth hormone secretagogue receptor-1a (GHSR-1a) and it is an endogenous ligand for this receptor. It has been also regarded as a potent vasodilatory peptide.\textsuperscript{20} Intravenous administration of ghrelin in healthy human volunteers produced significant reduction in peripheral vascular resistance and increased cardiac output without any significant change in heart rate.\textsuperscript{21} These cardiovascular responses mimic the hyperdynamic phase that is generally observed in the early stage of sepsis.\textsuperscript{3} The primary challenge in sepsis, however, is to prevent the transition from the early hyperdynamic phase to the late hypodynamic phase.

Since ghrelin has vasodilatory properties, we sought to determine whether ghrelin or its receptor, GHSR-1a, plays any role in the cardiovascular response to sepsis. Our study showed that while ghrelin levels decreased both at 5 hours and 20 hours after CLP, GHSR-1a mRNA expression was markedly elevated in early sepsis. Ghrelin-induced relaxation was also increased significantly during early sepsis but was not altered in late sepsis. These results suggest GHSR-1a expression is upregulated and vascular sensitivity to ghrelin stimulation is increased in the hyperdynamic phase of sepsis.\textsuperscript{22} Others have also shown that plasma ghrelin levels were significantly decreased in an animal model of endotoxemia as well.\textsuperscript{23} Therefore, these studies imply that ghrelin could be used as a treatment for sepsis.

Ghrelin has been reported to downregulate cytokines in human endothelial cells.\textsuperscript{24} However, the major source of inflammatory cytokines in sepsis are macrophages.\textsuperscript{25} In this regard, studies have demonstrated that treatment with ghrelin in a rat model of endotoxemia significantly decreased circulating levels of cytokines.\textsuperscript{26} Based on this knowledge, we sought to determine whether ghrelin can alter cytokine levels in CLP-induced sepsis. Our study showed that intravenous administration of ghrelin starting at 5 hours after CLP for 15 hours, markedly reduced both TNF-\(\alpha\) and interleukin (IL)-6 plasma and peritoneal fluid levels.\textsuperscript{27} These studies provided preclinical evidence that ghrelin is a beneficial therapeutic agent for sepsis.

**Mechanism of action of ghrelin in sepsis**

Although the beneficial role of ghrelin in downregulating cytokines was reported in several studies,\textsuperscript{24,26,27} the mechanism of action of ghrelin in sepsis has only been unraveled within the last few years. In this regard, whether the beneficial effect of ghrelin is mediated by its receptors on macrophages (Kupffer cells and peritoneal macrophages) was explored by us.\textsuperscript{27} To test the hypothesis, we treated Kupffer cells and peritoneal macrophages with lipopolysaccharide (LPS), a potent stimulator of cytokine production. When these cells were treated with LPS alone, as expected, a dramatic increase in TNF-\(\alpha\) and IL-6 levels were observed. In contrast, when these cells were co-incubated with ghrelin and LPS, TNF-\(\alpha\) and
机理的行动在败血症

**图 1** 肠道菌组败血症由盲肠结扎和刺破（CLP）激活交感神经系统（SNS）并导致去甲肾上腺素（NE）从肠道的释放。NE 通过门静脉进入肝脏。在肝脏中，NE 与 α_{2A}-adrenoceptors (α_{2A}-AR) 结合并激活负责 TNF-α，IL-6 和其他促炎细胞因子的信号通路，从而导致肝脏功能障碍。饥饿，一种来自胃的肽，通过穿过血脑屏障到达大脑的 dorsal vagal complex (DVC)，刺激 GHSR-1a 受体，激活迷走神经，进而通过胆碱能途径，通过 cAMP 水平的增加和恢复 MKP-1，降低 TNF-α 和 IL-6 从巨噬细胞的释放。因此，饥饿的有益作用在败血症中通过抑制 TNF-α 和 IL-6 释放来实现，同时激活交感和副交感神经系统。

IL-6 水平保持与 LPS 单独处理样本一样高。此研究表明，饥饿的有益作用在于减少败血症中细胞因子的释放不能直接通过其在巨噬细胞上的受体。

肝脏在败血症中的功能障碍是由促炎细胞因子的上调引起的，部分原因是交感神经系统的过度激活导致 NE 的释放。^{10} 因此，我们假设通过调节交感神经系统，饥饿可能降低 NE 的释放，从而减少细胞因子的释放。^{28} 如预期的那样，败血症产生显著增加血清 NE 和 TNF-α 水平。
at 2 hours after CLP. Intravenous administration of ghrelin markedly decreased these levels at 2 hours after CLP while administration of ghrelin in sham animals did not show any significant changes in either NE or TNF-α levels in plasma. In addition, intracerebroventricular (ICV) administration of ghrelin markedly decreased circulating levels of NE at 2 hours after CLP. Ghrelin’s inhibitory effect on plasma NE levels was completely abolished by ICV injection of the GHSR-1α antagonist. Interestingly, ghrelin’s inhibition on TNF-α levels was only partially blocked by ICV injection of GHSR-1α antagonist. Furthermore, co-administration with NE partially blocked ghrelin’s inhibitory effect on plasma TNF-α levels as well. Ghrelin treatment in septic rats significantly improved MKP-1 mRNA and protein levels from the vehicle group suggesting the inhibitory effect of ghrelin on TNF-α in sepsis may be mediated by MKP-1. These studies show that ghrelin’s beneficial effect in downregulating TNF-α in sepsis is at least in part mediated by the inhibition of the sympathetic nerve activation.

A large body of evidence indicated that the physiological function of ghrelin is mediated by the central and peripheral receptor distributions and that the wide array of GHSR presence suggests diverse pathways for ghrelin action. One of these studies demonstrates the presence of GHSR in afferent neurons of nodose ganglia, suggesting that ghrelin signals are transmitted to the brain by the vagal afferent nerves. It has also been shown that central administration of ghrelin stimulates the vagal efferent nerve in anesthetized rats. These studies suggest an important role for the vagus nerve in ghrelin’s physiological functions. Recent studies demonstrated that electrical stimulation of the vagus nerve subsequent to LPS administration in rats prevented the release of TNF-α from macrophages.

To determine if the vagus nerve plays any role in the beneficial effect of ghrelin in sepsis, the effect of ghrelin on TNF-α and IL-6 production in septic animals that underwent subdiaphragmatic vagotomy 5 hours after CLP were investigated. Ghrelin administration immediately following vagotomy completely prevented the inhibitory effect of ghrelin on the circulating levels of TNF-α and IL-6 during late sepsis. In contrast, ghrelin treatment in animals which did not undergo vagotomy exhibited the anti-inflammatory effect of ghrelin during late sepsis. In addition, vagotomy completely prevented the inhibitory effect of ghrelin on the peritoneal fluid levels of TNF-α and IL-6 during late sepsis as well. However, ghrelin treatment in non-vagotomized rats significantly decreased peritoneal fluid levels of these cytokines during late sepsis. Vagotomy also abrogated ghrelin’s protective effect on sepsis-induced organ function parameters such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate. These studies clearly indicated that ghrelin’s beneficial effect in sepsis is mediated by the vagus nerve. These studies collectively demonstrated that ghrelin’s beneficial effect in inhibiting cytokine release in sepsis is mediated by a combined action of the activation of the vagus nerve and the inhibition of the sympathetic nervous system (Figure 1).

**Mechanism of action of ghrelin in age-related inflammation in sepsis**

It is well recognized that the morbidity and mortality associated with sepsis increases with age. It has also been thought that there is a decline in immune function in the elderly, leading to an inadequate inflammatory response which results in increased morbidity and mortality. However, the impairment of immune function in aging could be due to an uncontrolled inflammatory response leading to excess production of pro-inflammatory cytokines such as TNF-α and IL-6. This notion is supported by our recent studies showing that aging exacerbates the pro-inflammatory response and worsens tissue injury in endotoxemia. We also examined whether ghrelin has any role in the hyperinflammatory state observed in septic aged rats. Our studies show that while basal plasma ghrelin levels were significantly elevated in the aged rats, endotoxemia produced greater decrease in ghrelin in aged rats as compared to young rats. Similarly, the gene and protein expressions of the ghrelin receptor were significantly decreased in the dorsal vagal complex of aged rats as compared to young rats. Surprisingly, administration of ghrelin failed to protect the aged rats from endotoxemia.

Ghrelin was originally reported to induce growth hormone (GH) release through the pituitary GHSR-1α stimulation. In humans, GH levels decline approximately 15% per decade after age 25. The decline in GH with age is associated with many adverse effects that occur with aging. Based on this information, we examined if GH levels were altered in aged rats and, more importantly, whether GH levels have any role in the hyperinflammatory state observed in the aged rats with endotoxemia. Our results indicated that plasma GH levels were markedly decreased in aged rats as compared to young rats. Interestingly, when these rats were treated with GH, the ghrelin receptor gene and protein expressions in the dorsal vagal complex increased significantly in aged rats. However, the GH treatment did not alter either the cytokine levels or the organ injury markers in the endotoxemic aged rats suggesting GH alone is not sufficient to prevent the hyperinflammatory state in aged rats. In contrast, coadministration...
of ghrelin and GH significantly decreased the inflammatory response and organ injury in the aged rats\(^\text{16}\) indicating that ghrelin’s hyporesponsiveness due to a decrease in growth hormone contributes to the aged related hyperinflammatory state in sepsis.

**Mechanism of action of ghrelin in radiation combined injury (RCI)**

We have recently shown that plasma ghrelin levels were markedly decreased in a rat model of radiation combined injury (RCI), polymicrobial sepsis induced by CLP in combination with whole body radiation.\(^\text{39}\) Intravenous administration of ghrelin in RCI markedly reduced plasma NE levels as compared to RCI rats treated with vehicle.\(^\text{39}\) In addition, ghrelin treatment in RCI produced significant decrease in plasma TNF-\(\alpha\) and IL-6, gut tissue levels of TNF-\(\alpha\) and IL-6 and myeloperoxidase (MPO) activities of the gut, lungs and kidneys demonstrating that ghrelin is indeed beneficial in downregulating the inflammatory response induced by RCI.\(^\text{39}\) This indicates that ghrelin’s protective effect in RCI is mediated by the sympathetic nerve activation.

To determine if ghrelin’s effect in RCI is also mediated by the activation of the vagus nerve, vagotomized RCI rats were examined for the inflammatory responses and organ injury parameters. Our results indicated that both non-vagotomized and vagotomized RCI rats exhibited increased circulating levels of inflammatory cytokines and organ injury markers compared to sham operated animals.\(^\text{39}\) Likewise, tissue MPO levels were also significantly increased. In contrast, ghrelin treatment in non-vagotomized RCI rats produced markedly reduced levels of these inflammatory parameters.\(^\text{39}\) However, ghrelin treatment did not reduce these levels in vagotomized RCI rats. This study indicated that ghrelin’s beneficial effect in RCI is mediated by the vagus nerve. These studies collectively suggest the protective effect of ghrelin in RCI is to be attributed to balancing of the dysregulated sympathetic and parasympathetic nervous system caused by the injuries.

**Future studies and perspectives**

Understanding the pathophysiology of sepsis as it relates to the liver is extremely crucial because the liver is believed to be the primary organ responsible for the multi-organ failure in sepsis. In this regard, we have already demonstrated that even at the early stage of sepsis, hepatic function is depressed due to the upregulation of cytokine production from the liver caused by the increased release of NE from the gut. Therefore, therapy towards sepsis should be directed even at the early stages of sepsis when cardiovascular response appears to be rather normal. Since ghrelin is able to inhibit the early rise in NE levels, ghrelin could be such a candidate for therapy.

In addition, it is also well recognized that vagus nerve stimulation could be beneficial in sepsis. Due to the fact that ghrelin activates the vagus nerve, ghrelin can potentially provide the benefit caused by the vagus nerve stimulation. On the other hand, ghrelin can inhibit the sympathetic nerve activation causing the decrease in NE release and subsequent inhibition of the pro-inflammatory cytokines from the liver during sepsis.

Although our *in vitro* studies strongly suggest that ghrelin’s inhibitory effect on pro-inflammatory cytokine release from the liver and the peritoneal macrophages is not mediated by ghrelin receptors on macrophages, it is not known if ghrelin can protect against the increase in pro-inflammatory cytokines caused by sepsis mediators other than NE. Since ghrelin decreases the mortality of septic animals, it is plausible that ghrelin can be protective against other mediators. Future studies are needed for such a concept.

In aging, we show that ghrelin’s hyporesponsiveness attributes to the hyperinflammatory state observed in sepsis and that GH upregulates the ghrelin receptors in the dorsal vagal complex and thus increase the activity of ghrelin. We also show here ghrelin is beneficial in RCI, an experimental model to mimic clinical situation related to the terrorist radiation exposure scenario. In RCI, the protective effect of ghrelin is balancing the dysregulated sympathetic/parasympathetic nervous system caused by the injuries. Future studies are needed to determine whether ghrelin can be beneficial in other acute inflammatory conditions such as hemorrhagic shock and ischemia/reperfusion injury. Nevertheless, the data reviewed herein strongly indicate that ghrelin can be further developed as a potential therapy for sepsis.

**Acknowledgements/Disclosures**

This work is supported by the National Institutes of Health grants, R01 GM053008, R01 AG 028352 and R21 AI 080536 (P.W.). The authors report no conflicts of interest.

**References**


Hepatic Medicine: Evidence and Research

Publish your work in this journal

Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access journal covering all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease; Investigation and treatment of hepatic disease; Pharmacology of drugs used for the treatment of hepatic disease. Issues of patient safety and quality of care will also be considered. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/hepatic-medicine-evidence-and-research-journal

Hepatic Medicine: Evidence and Research 2010:2


